GHR Foundation
  • Impact Areas
    • Global Engagement >
      • Children in Families
      • Prepare The Future
      • Programs in Transition >
        • BridgeBuilder >
          • Overview
          • 2017 Top Ideas >
            • Peace Direct
            • BioCarbon Engineering
            • LIFT Chicago
            • Local Youth Corner Cameroon
            • NaTakallam
          • 2018 Top Ideas >
            • This is My Backyard
            • Found in Translation
            • Producers Direct
            • War Child Canada
            • My Choices Foundation
          • 2019 Top Ideas >
            • Top Manta
            • Five One Labs
            • SAMA for All
            • Talent Beyond Boundaries
            • FaithAction
        • Inter-Religious Action
        • Sister Support
    • Education >
      • Catholic Schools
      • Higher Education
    • Twin Cities Racial Equity
    • Alzheimer's
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • FAQs
    • Grants & Financials
  • Contact

Nature: Could drugs prevent Alzheimer’s? These trials aim to find out

6/30/2022

0 Comments

 
Picture
Trial coordinator Eric McDade assesses participant Marty Reiswig for cognitive ability. Credit: Matt Miller/Washington University School of Medicine
From Nature:

"Aisen foresees a future — maybe just a decade or so down the line — in which much of the burden of Alzheimer’s disease might actually be prevented. “We’re heading towards screening people from middle age on with blood tests, and treating those who show amyloid abnormalities with drugs that reduce the generation of amyloid plaques,” he says. “I am optimistic.”

A lot needs to go right for this hopeful view to become reality. Large clinical trials will have to show that these therapies work, and amyloid-clearing drugs will have to be proven to be safe and affordable. After decades of setbacks and failed clinical trials, some dementia researchers prefer to express caution. “The field is taking tremendous risks by engaging in studies that can cost billions of dollars,” says neurologist David Knopman at the Mayo Clinic in Rochester, Minnesota.

It will take a while for answers to emerge. Some trials of Alzheimer’s disease prevention are just getting started, and some ongoing ones could stretch into the next decade."

Read more. 
0 Comments

Wash U: New Alzheimer’s prevention trial in young people

1/5/2022

0 Comments

 
Picture
Neurologist Eric McDade, DO, meets with Marty Reiswig, a participant in Alzheimer’s prevention trials at Washington University School of Medicine in St. Louis. Reiswig comes from a family with a genetic mutation that puts carriers at high risk of developing Alzheimer’s. McDade is the director of a new Alzheimer’s prevention trial involving young adults from high-risk families. The trial is evaluating whether an investigational drug can clear a key Alzheimer’s protein called amyloid beta, and slow or stop the disease.
From Washington University School of Medicine in St. Louis:

Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold – up to 25 years before the expected onset of dementia.

Called the Primary Prevention Trial, the new study will investigate whether gantenerumab — an investigational antibody under development for Alzheimer’s disease by Roche and Genentech, a member of the Roche Group — can clear a key Alzheimer’s protein called amyloid beta, and slow or stop the disease. Amyloid is the chief component of plaques that dot the brains of people with the disease. Many scientists suspect the disease originates from the buildup of amyloid plaques in the brain that start to develop up to two decades before symptoms of dementia begin.

“Overwhelming evidence suggests that the most effective way to slow or stop amyloid beta is to prevent it from building up in the first place, but most of the drugs targeted to this protein have been tested in people who already have at least some early signs of the disease, such as memory loss – when the disease is far enough along that reducing amyloid alone isn’t likely to stop it,” said Eric McDade, DO, an associate professor of neurology and the trial’s principal investigator. “We’ll be recruiting participants as young as 18. In many ways, this trial will be a necessary test of the amyloid hypothesis, which has had a major influence on Alzheimer’s research and drug development over the past 30 years.”

The new trial involves families with rare genetic mutations that cause Alzheimer’s at a young age – typically in a person’s 50s, 40s or even 30s. A parent with such a mutation has a 50% chance of passing the genetic mutation to a child, and any child who inherits the mutation is all but guaranteed to develop symptoms of dementia near the same age as his or her parent. This certainty gives researchers an opportunity to evaluate the effectiveness of drugs designed to prevent Alzheimer’s.

“It’s exciting to think of the valuable insights this groundbreaking trial will provide in the prevention of Alzheimer’s dementia,” said Fred Miller, GHR Foundation’s chief operating officer and Alzheimer’s program lead. “We’re pleased to partner boldly on the multiple DIAN-TU trials, all made possible by the strong collaboration between academic researchers, government, industry, philanthropy and the DIAN families themselves.”​

Read more.
0 Comments

Wash U: Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates

2/10/2020

1 Comment

 
Picture
Picture
Randall J. Bateman, MD, of Washington University School of Medicine in St. Louis, led an international trial evaluating whether investigational drugs could slow memory loss and cognitive decline in a rare, inherited form of Alzheimer's disease. The trial was conducted at 24 sites in Australia, Canada, France, Spain, the United Kingdom and the United States.
From Washington University School of Medicine in St. Louis: 

"An international clinical trial evaluating whether two investigational drugs can slow memory loss and cognitive decline in people in the early stages of a rare, inherited form of Alzheimer’s disease has yielded disappointing results, an initial analysis of the data has shown. However, the researchers continue to explore data from the trial’s cognitive and clinical outcomes, and await analyses of biomarkers and other information so they can further understand the study’s results."

Read more...
1 Comment

NYT: An Alzheimer’s Treatment Fails: ‘We Don’t Have Anything Now’

2/10/2020

0 Comments

 
Picture
Picture
From The New York Times:

"The study aimed to show that Alzheimer’s disease could be stopped if treatment began before symptoms emerged. The participants were the best candidates that scientists could find: still healthy, but with a rare genetic mutation that guaranteed they would develop dementia.

Now, the verdict is in: The drugs did nothing to slow or stop cognitive decline in these subjects, dashing the hopes of scientists.
​
The results are a deep disappointment, scientists said — but not a knockout punch. The drugs did not work, but the problems may be fixable: perhaps the doses were too low, or they should have been given to patients much younger."

Read more...
0 Comments

Pioneering Alzheimer’s Prevention Study Starts Enrollment

8/29/2016

 
Picture
GHR’s Health initiative partners with organizations using innovative trials to pursue the prevention of Alzheimer’s disease. One such trial is the Alzheimer’s Prevention Initiative (API) Generation Study which recently began enrollment in high-risk older adults to validate the use of genetic screening and identify an effective approach to prevent the disease.

Led by Dr. Eric Reiman and Dr. Pierre Tariot of Banner Alzheimer’s Institute (BAI), this pioneering multi-site prevention study is working to determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of Alzheimer’s symptoms in people at a high genetic risk of developing the disease. The study will involve more than 1,300 cognitively healthy adults, age 60 to 75, who have inherited a copy of the e4 type of the apolipoprotein (APOE) gene from each parent. Roughly one in four people carry a single copy of the gene, which is strongly linked to late-onset Alzheimer’s.

The Generation Study is part of the API, an international collaborative led by BAI to accelerate the evaluation of promising treatments. The study is sponsored by Swiss pharmaceutical company Novartis and Thousand Oaks, Calif.-based biotechnology company Amgen in collaboration with BAI, with funding from the National Institute on Aging—part of the National Institutes of Health—as well as GHR, Alzheimer’s Association, Fidelity Biosciences Research Institute and Banner Alzheimer’s Foundation.

To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us.

Fight Against Alzheimer’s Focuses on Prevention

8/12/2014

0 Comments

 
Picture
Photo credit: The Mayo Clinic
GHR Foundation attended the Alzheimer’s Association International Conference. As an important platform to present research and trend information, the forum saw global news coverage on potential new diagnostics, findings related to lifestyle and international rates of prevalence. 

A Wall Street Journal piece covering the conference entitled “Alzheimer's Disease Fight Focuses on Preventive Treatment” reinforces GHR’s focus on funding effective prevention therapies. It notes that “greater ability to measure the progression of the disease in the brain through the use of biological markers, such as the imaging of disease-related proteins, has made it easier to detect the subtle and slow progression of the disease...”

To advance our Alzheimer’s strategy, GHR’s Alzheimer’s advisory council convened a strategic meeting at the conference to discuss the impact of research, potential collaboration and next steps. The Foundation is pleased to be partnering with so many public and private sectors leaders in the fight against Alzheimer’s disease.
0 Comments

GHR Supports Research Grant to Expand A4 Alzheimer’s Prevention Trial

3/5/2014

0 Comments

 
Picture
Photo credit: The Mayo Clinic
With a focus on Alzheimer’s disease prevention research, GHR Foundation funded a groundbreaking Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study which may help identify people who are highest risk to develop the disease. This research will also identify treatments – and when to best administer them – to slow or prevent Alzheimer’s. Long-term, the Foundation hopes the A4 study and complementary research will result in FDA approval for Alzheimer’s prevention therapies.

The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video. 

GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.  

0 Comments

    Categories

    All
    A4
    Africa
    Alzheimer's
    Alzheimer's Association
    Annual Report
    BridgeBuilder
    C2N
    Cambodia
    Catholic Schools
    Central African Republic
    Children In Families
    Coverage
    COVID 19
    COVID-19
    Design Build
    Develop Diagnostics
    DIAN
    DIAN Primary Prevention
    DIAN TU
    DIAN-TU
    Education
    Faith & Development
    Global
    Global Development
    Health
    Higher Education
    Inter-Religious Action
    Kenya
    La Jolla Institute
    Legacy
    Mayo Clinic
    Mayo Clinic Study Of Aging
    Myanmar
    Nepal
    Nigeria
    NIH NIA
    NIH-NIA
    Observational Studies
    Podcast
    PrecivityAD
    Prevention Trials
    Sister Support
    Solutions
    Twin Cities Racial Equity
    Uganda
    U.S.
    Work Of The Church
    Zambia

    Archives

    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    August 2014
    July 2014
    May 2014
    April 2014
    March 2014
    October 2013
    December 2012

    RSS Feed

CONNECT WITH US

IMPACT AREAS  |  NEWS  |  ABOUT  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2022 GHR FOUNDATION
All Rights Reserved.